National Institute on Drug Abuse; Amended Notice of Meeting, 2627-2628 [2024-00667]
Download as PDF
<![CDATA[
Federal Register / Vol. 89, No. 10 / Tuesday, January 16, 2024 / Notices
Federal partners, academic institutions,
the private sector, health professionals,
professional societies, advocacy groups,
patient communities, and other
interested members of the public.
DATES: The NIH-wide Strategic Plan for
Autoimmune Disease Research Request
for Information is open for public
comment through March 1, 2024.
Comments must be received by March 1,
2024, to ensure consideration.
Comments received after the public
comment period has closed may be
considered by the Office of
Autoimmune Disease Research within
the Office of Research on Women’s
Health.
Submissions must be
submitted electronically via the
following website: https://rfi.grants.nih.
gov/?s=656f78c997c67a6239036b22.
FOR FURTHER INFORMATION CONTACT:
Questions about this request for
information should be directed to Vicki
Shanmugam, MBBS, MRCP, FACR,
CCD, Director, Office of Autoimmune
Disease Research, Office of Research on
Women’s Health, 6707 Democracy
Boulevard, Bethesda, MD 20892, oadrorwh#rfi@od.nih.gov, 301–402–1770.
SUPPLEMENTARY INFORMATION: This
notice is in accordance with the 21st
Century Cures Act, wherein NIH and its
institutes are required to regularly
update their strategic plans. In 2022, the
National Academies of Sciences,
Engineering, and Medicine report,
Enhancing NIH Research on
Autoimmune Diseasehttps://pubmed.
ncbi.nlm.nih.gov/35593778/%22%20/
l%20%22:∼:text=Enhancing%20NIH
%20Research%20on%20Autoimmune
%20Disease%20also%20calls,years%29
%20to%20study%20disease%20across
%20the%20life%20course, examined
NIH research efforts related to
autoimmune diseases. Subsequently,
Congress, via the Joint Explanatory
Statement https://www.appropriations.
senate.gov/imo/media/doc/Division
%20H%20-%20LHHS%20Statement
%20FY23.pdf accompanying the Fiscal
Year 2023 Consolidated Appropriations
Act, 2023 directed the establishment of
an Office of Autoimmune Disease
Researchhttps://orwh.od.nih.gov/oadrorwh within the Office of Research on
Women’s Health (OADR–ORWH)
https://orwh.od.nih.gov/ and directed
OADR–ORWH to:
• Coordinate development of a multiinstitute and center (IC) strategic
research plan;
• Identify emerging areas of
innovation and research opportunity;
• Coordinate and foster collaborative
research across ICs;
ddrumheller on DSK120RN23PROD with NOTICES1
ADDRESSES:
VerDate Sep<11>2014
18:57 Jan 12, 2024
Jkt 262001
• Annually evaluate the NIH
autoimmune disease research portfolio;
• Provide resources to support
planning, collaboration, and innovation;
and
• Develop a publicly accessible
central repository for autoimmune
disease research.
Currently, various NIH institutes,
centers, and offices (ICOs) support
autoimmune disease research in
alignment with their individual mission
areas. Establishing an NIH-wide
Strategic Plan for Autoimmune Disease
Research will allow OADR–ORWH to
amplify ICO efforts and create
opportunities for synergistic innovation
focused on areas of autoimmune disease
research that will benefit from multiICO partnerships and opportunities to
implement cross-cutting research.
Information Requested
NIH is seeking input from internal
and external partners throughout the
scientific research, advocacy, and
clinical practice communities, including
those employed by NIH and by
institutions receiving NIH support, as
well as the public, on the following key
areas related to autoimmune disease
research:
Objective 1: Research areas that would
benefit from cross-cutting, collaborative
research (these areas may include basic
or translational research, clinical
research, health services research,
population science, data science,
preventative research, biomedical
engineering, and other areas of
research).
Objective 2: Opportunities to advance
collaborative, innovative, or
interdisciplinary areas of autoimmune
disease research.
Objective 3: Opportunities to improve
outcomes for individuals living with
autoimmune diseases including NIHdesignated health disparities
populations https://
www.nimhd.nih.gov/about/overview/,
populations and individuals with rare
diseases, and specific populations that
have been historically underrepresented
in research and clinical trials.
Objective 4: Cross-cutting areas that
are integral to advancing autoimmune
disease research at NIH including
development of a publicly accessible
central repository for autoimmune
disease research, sex- and genderintentional research design across all
stages of research, and engagement of all
populations in research and clinical
trials.
Responses to this RFI are voluntary
and are meant for information and
planning purposes only. Do not include
any proprietary, classified, confidential,
PO 00000
Frm 00046
Fmt 4703
Sfmt 4703
2627
trade secret, or sensitive information in
your response. Respondents are advised
that the responses are reviewed by NIH
staff, and the U.S. government is under
no obligation to acknowledge receipt of
the information provided or provide
feedback to the respondents. This RFI is
for planning purposes only and should
not be construed as a solicitation, grant,
or cooperative agreement, or as an
obligation on the part of the federal
government, the NIH, or individual NIH
institutes, centers, and offices to provide
any kind of support for any ideas
identified in response to it.
The government may use the
information submitted in response to
this RFI at its discretion. The
government reserves the right to use any
submitted information on public NIH
websites, in reports, in summaries of the
state of the science, in any possible
resultant solicitation(s), grant(s), or
cooperative agreement(s), or in the
development of future funding
announcements.
The government will not pay for the
preparation of any information
submitted or for the government’s use of
such information. No basis for claims
against the U.S. government shall arise
as a result of a response to this request
for information or from the
government’s use of such information.
NIH looks forward to your input, and
we hope that you will share this RFI
document with your colleagues.
Dated: January 6, 2024.
Lawrence A. Tabak,
Principal Deputy Director, National Institutes
of Health.
[FR Doc. 2024–00695 Filed 1–12–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Amended Notice of Meeting
Notice is hereby given of a change in
the meeting of the National Institute on
Drug Abuse Special Emphasis Panel,
February 13, 2024, 10:00 a.m. to
February 14, 2024, 05:00 p.m., National
Institute of Health, National Institute on
Drug Abuse, 301 North Stonestreet
Avenue, Bethesda, MD 20892 which
was published in the Federal Register
on November 24, 2023, FR Doc 2023–
25938, 88 FR 82387.
This notice is being amended to
change the meeting date from February
13–14, 2024 to February 14, 2024. The
meeting time and location will remain
E:\FR\FM\16JAN1.SGM
16JAN1
2628
Federal Register / Vol. 89, No. 10 / Tuesday, January 16, 2024 / Notices
the same. The meeting is closed to the
public.
Dated: January 10, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–00667 Filed 1–12–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Aging; Notice of
Closed Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
ddrumheller on DSK120RN23PROD with NOTICES1
Name of Committee: National Institute on
Aging Special Emphasis Panel; Healthcare
Decision Making.
Date: January 30, 2024.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute on Aging,
Gateway Building, 7201 Wisconsin Avenue,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Kimberly Firth, Ph.D.,
National Institutes of Health, National
Institute on Aging, Gateway Building, 7201
Wisconsin Avenue, Suite 2C212, Bethesda,
MD 20892, 301–402–7702, firthkm@
mail.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.866, Aging Research,
National Institutes of Health, HHS)
Dated: January 10, 2024.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–00671 Filed 1–12–24; 8:45 am]
BILLING CODE 4140–01–P
VerDate Sep<11>2014
18:57 Jan 12, 2024
Jkt 262001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of General Medical
Sciences; Notice of Closed Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
General Medical Sciences Initial Review
Group; Training and Workforce Development
Study Section—C Training and Workforce
Development Study Section C (TWD–C)—
Review of B2B, B2D and IRACDA.
Date: February 22, 2024.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute of General Medical
Sciences, Natcher Building, 45 Center Drive,
Bethesda, Maryland 20892 (Virtual Meeting).
Contact Person: Sonia Ivette OrtizMiranda, Ph.D., Scientific Review Officer,
Scientific Review Branch, National Institute
of General Medical Sciences, National
Institutes of Health, 45 Center Drive, MSC
6200 Bethesda, Maryland 20892, 301–402–
9448, sonia.ortiz-miranda@nih.gov.
(Catalogue of Federal Domestic Assistance
Program No. 93.859, Biomedical Research
and Research Training, National Institutes of
Health, HHS)
Dated: January 9, 2024.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–00635 Filed 1–12–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Aging; Notice of
Closed Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
PO 00000
Frm 00047
Fmt 4703
Sfmt 4703
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Aging Special Emphasis Panel; Brain Aging
Models.
Date: February 21, 2024.
Time: 10:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute on Aging,
Gateway Building, 7201 Wisconsin Avenue,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Bita Nakhai, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, National Institute on Aging, 7201
Wisconsin Avenue Gateway Bldg., Suite
2C212, Bethesda, MD 20892, 301–402–7701,
nakhaib@nia.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.866, Aging Research,
National Institutes of Health, HHS)
Dated: January 10, 2024.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–00670 Filed 1–12–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Center for Complementary &
Integrative Health; Notice of Closed
Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Center for
Complementary and Integrative Health
Special Emphasis Panel; NCCIH Training and
Education Review Panel (CT).
Date: March 7–8, 2024.
Time: 10:00 a.m. to 4:00 p.m.
E:\FR\FM\16JAN1.SGM
16JAN1
]]>Agencies
[Federal Register Volume 89, Number 10 (Tuesday, January 16, 2024)]
[Notices]
[Pages 2627-2628]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-00667]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Amended Notice of Meeting
Notice is hereby given of a change in the meeting of the National
Institute on Drug Abuse Special Emphasis Panel, February 13, 2024,
10:00 a.m. to February 14, 2024, 05:00 p.m., National Institute of
Health, National Institute on Drug Abuse, 301 North Stonestreet Avenue,
Bethesda, MD 20892 which was published in the Federal Register on
November 24, 2023, FR Doc 2023-25938, 88 FR 82387.
This notice is being amended to change the meeting date from
February 13-14, 2024 to February 14, 2024. The meeting time and
location will remain
[[Page 2628]]
the same. The meeting is closed to the public.
Dated: January 10, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2024-00667 Filed 1-12-24; 8:45 am]
BILLING CODE 4140-01-P
